Abstract
Cancer cells display an overproduction of reactive oxygen species resulting from an exaggerated intrinsic oxidative stress. However, the concept of deleterious oxidants versus beneficial antioxidants has recently evolved. Indeed, molecules like natural coumarins have shown anti-oxidant or pro-oxidant properties depending on their intracellular concentration. Therefore, we have investigated the structure-activity relationship of a variety of coumarin derivatives in terms of cytotoxicity towards human and murine carcinoma cell lines (HT29, HepG2, A549, MCF7, OVCAR and CT26). Amongst those compounds, (E)-7-methoxy-4-(3-oxo-3- phenylprop-1-enyl)-2H-chromen-2-one and (E)-7-hydroxy-4-(3-(4-hydroxyphenyl)-3-oxoprop-1-enyl)-2H-chromen-2-one displayed the most potent cytotoxic effect on colon cancer cells, CT26, (IC50=4.9µM) linked to their pro-oxidant properties. Those compounds triggered the in vitro production of reactive oxygen species by tumor cells, leading to their death through a necrotic process. In vivo, molecules also slowed down tumor growth by 65.7% and 35.4%, respectively, without inducing significant side effects.
Keywords: Cancer, coumarin, cytotoxicity, oxidative stress, structure-activity relationship.
Anti-Cancer Agents in Medicinal Chemistry
Title:Chalcone-Coumarin Derivatives as Potential Anti-Cancer Drugs: An in vitro and in vivo Investigation
Volume: 14 Issue: 7
Author(s): Vincent Jamier, Wioleta Marut, Sergio Valente, Christiane Chereau, Sandrine Chouzenoux, Carole Nicco, Herve Lemarechal, Bernard Weill, Gilbert Kirsch, Claus Jacob and Frederic Batteux
Affiliation:
Keywords: Cancer, coumarin, cytotoxicity, oxidative stress, structure-activity relationship.
Abstract: Cancer cells display an overproduction of reactive oxygen species resulting from an exaggerated intrinsic oxidative stress. However, the concept of deleterious oxidants versus beneficial antioxidants has recently evolved. Indeed, molecules like natural coumarins have shown anti-oxidant or pro-oxidant properties depending on their intracellular concentration. Therefore, we have investigated the structure-activity relationship of a variety of coumarin derivatives in terms of cytotoxicity towards human and murine carcinoma cell lines (HT29, HepG2, A549, MCF7, OVCAR and CT26). Amongst those compounds, (E)-7-methoxy-4-(3-oxo-3- phenylprop-1-enyl)-2H-chromen-2-one and (E)-7-hydroxy-4-(3-(4-hydroxyphenyl)-3-oxoprop-1-enyl)-2H-chromen-2-one displayed the most potent cytotoxic effect on colon cancer cells, CT26, (IC50=4.9µM) linked to their pro-oxidant properties. Those compounds triggered the in vitro production of reactive oxygen species by tumor cells, leading to their death through a necrotic process. In vivo, molecules also slowed down tumor growth by 65.7% and 35.4%, respectively, without inducing significant side effects.
Export Options
About this article
Cite this article as:
Jamier Vincent, Marut Wioleta, Valente Sergio, Chereau Christiane, Chouzenoux Sandrine, Nicco Carole, Lemarechal Herve, Weill Bernard, Kirsch Gilbert, Jacob Claus and Batteux Frederic, Chalcone-Coumarin Derivatives as Potential Anti-Cancer Drugs: An in vitro and in vivo Investigation, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (7) . https://dx.doi.org/10.2174/1871520613666131224124445
DOI https://dx.doi.org/10.2174/1871520613666131224124445 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Histone Deacetylase Inhibitors in Psoriasis Therapy
Current Drug Targets - Inflammation & Allergy Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Novel Drug Targets in Malaria Parasite with Potential to Yield Antimalarial Drugs with Long Useful Therapeutic Lives
Current Pharmaceutical Design The Emerging Role of Bcr-Abl-Induced Cystoskeletal Remodeling in Systemic Persistence of Leukemic Stem Cells
Current Drug Delivery Cancer Drug Discovery Targeting Histone Methyltransferases: An Update
Current Medicinal Chemistry Imaging in the Age of Molecular Medicine: Monitoring of Anti-Angiogenic Treatments
Current Pharmaceutical Biotechnology Synthesis and Applications of Glyconanoparticles
Current Organic Chemistry PSMA7, A Potential Biomarker of Diseases
Protein & Peptide Letters Status of Anti-Lung Cancer Drug Patents Applications in China from 2003 to 2012
Recent Patents on Anti-Cancer Drug Discovery Strategies for the Design of Potent and Selective Kinase Inhibitors
Current Pharmaceutical Design Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Current Cancer Drug Targets Anthraquinones: Analytical Techniques as a Novel Tool to Investigate on the Triggering of Biological Targets
Current Drug Targets Stem Cell Genetic Therapy for Fanconi Anemia – A New Hope
Current Gene Therapy Multiple Metamorphoses of CD38 from Prognostic Marker to Disease Modifier to Therapeutic Target in Chronic Lymphocytic Leukemia
Current Topics in Medicinal Chemistry Characterisation of Small Supernumerary Marker Chromosomes (sSMC) in Human
Current Genomics MicroRNA Polymorphisms, MicroRNA Pharmacogenomics and Cancer Susceptibility
Current Pharmacogenomics and Personalized Medicine Quantitative Ultrasound in Diagnosis of Metabolic Bone Diseases
Current Medical Imaging Current Management of Neonatal Neuroblastoma
Current Pediatric Reviews Importance of Influx and Efflux Systems and Xenobiotic Metabolizing Enzymes in Intratumoral Disposition of Anticancer Agents
Current Cancer Drug Targets Rhein Derivatives, A Promising Pivot?
Mini-Reviews in Medicinal Chemistry